This Combined Synopsis/Solicitation opportunity from Department Of Defense was posted on January 15, 2025. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Neonatal TPN Compounding and Methemoglobin Testing

Closed

HT941025N0022Federal

Submission Closed01/30/2025, 09:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325412

New

International

Pralidoxime Chloride/Methyl Sulfate ManufacturingThis subcontract involves the manufacture and supply of Pralidoxime chloride or methyl sulfate in solution or powder form for injection to support prime contractors on Department of National Defence projects. The required product must have a dosage strength of at least 200 mg per container and a minimum shelf-life of 36 months. The selected provider is responsible for conducting stability testing, providing quality assurance certification, and delivering complete treatment courses along with stability reports and product monographs. To be eligible, the manufacturer must hold a Health Canada Notice of Compliance under Division 8 or Division 11 authorization. This global procurement opportunity is managed by the Government of Canada and allows for performance across various international regions. Interested parties must submit their responses by November 10, 2026.

Department of National Defence

POSTED

DEADLINE

SLS Printer Consumables and Maintenance KitsThis subcontract focuses on the provision of specialized consumables and wear-and-tear replacement parts to support prime contractors working on Department of National Defence projects for the Government of Canada. The scope of supply includes engineering-grade thermoplastic powders such as PA 11, PA 12, PP, and TPU, along with critical SLS hardware components including optical cassettes, recoater blades, infrared heaters, sealing foam gaskets, and build chambers. All bulk consumables and spare parts kits are to be delivered to CFB Petawawa. The opportunity was posted on October 20, 2026, with a response deadline of November 2, 2026, falling under NAICS code 325412.

Department of National Defence

POSTED

DEADLINE

Supplier of Red Sealing Compound (NSN 8030015650423)This subcontract involves the supply of red sealing compound, identified by NSN 8030015650423, for prime contractors working under the Defense Logistics Agency. The material must be provided in 10.00 milliliter containers and strictly adhere to the DLA Master List of Technical and Quality Requirements RA001. The supplier is responsible for managing TYPE I (CODE H) shelf-life requirements and ensuring all packaging complies with MIL-STD-2073-1E and MIL-STD-129 standards. Additionally, the contractor must provide all necessary safety documentation, including SDS and HazCom labels in accordance with 29 C.F.R. 1910.1200. The performance of this contract is centered in FPO 09591-0100, with the primary objective being the delivery of packaged sealing compound and its associated safety certifications to the Department of Defense.

Defense Logistics Agency

POSTED

DEADLINE

Active Pharmaceutical Ingredient (API) SupplyThis subcontract for Active Pharmaceutical Ingredient (API) Supply involves the synthesis, purification, and bulk delivery of pharmaceutical-grade Benzocaine and Menthol. The provider supports prime contractors fulfilling requirements for the Department of Defense Medical Supply Chain Pharm FSA, ensuring all raw chemical components meet strict USP and ISO manufacturing standards through the use of HPLC purity testing. The performance of this contract is centered at Fort Campbell, Kentucky, under NAICS code 325412. The solicitation was posted on October 19, 2026, with a response deadline of October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Benzocaine and Menthol Lozenge SupplyThis subcontract involves the manufacture and supply of finished Benzocaine and Menthol lozenges to prime contractors supporting the Department of Defense Medical Supply Chain Pharm FSA. The provider is responsible for producing and quality-testing pharmaceutical lozenges within FDA-compliant facilities adhering to Good Manufacturing Practice standards to ensure all delivered quantities meet strict government specifications. Administrative processes for this requirement are managed through the DLA Internet Bid Board System for quote submissions. The performance of the contract is centered at Fort Campbell, and the procurement falls under NAICS code 325412 for pharmaceutical preparation.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Moxifloxacin Hydrochloride Tablets (400 MG)This subcontract, managed by the Medical Supply Chain Pharm FSA under the Department of Defense, involves the manufacture and supply of pharmaceutical-grade Moxifloxacin Hydrochloride Tablets (400 MG). The contractor is responsible for providing the antibiotic tablets in 30-count bottles, ensuring all products are sourced or manufactured in accordance with Good Manufacturing Practices and FDA approval and registration requirements. Logistical compliance is critical, as the contract mandates adherence to RP001 DLA Packaging Requirements and the use of climate-controlled storage and transport to maintain product integrity. Performance will take place in FPO 09591, with the primary objective of supporting prime contractors on DLA supply contracts.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Activated Charcoal, SuspensionThis subcontract, issued by the Medical Supply Chain Pharm FSA under the Department of Defense, requires the provision of activated charcoal in suspension form, identified by NSN 6505012828880. The materials must be delivered to the USS Lewis B Puller ESB 3, with all shipments adhering to strict DLA packaging requirements and technical specifications. The contract falls under NAICS code 325412 and is intended for prime contractors supporting DLA supply operations. Resellers are specifically required to comply with the Non-Manufacturer Rule to ensure eligibility. The performance location is designated as FPO 09591, with a response deadline set for October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of 4% Chlorhexidine Gluconate Surgical DetergentThis subcontract involves the supply of FDA-regulated 4% Chlorhexidine Gluconate surgical detergent for prime contractors supporting Department of Defense supply contracts. The provider is responsible for manufacturing or sourcing the chemical compound in strict accordance with NSN 6505-01-101-3759 specifications and DLA Packaging Requirements RP001. To maintain quality and regulatory compliance, the product must be produced in FDA-approved pharmaceutical manufacturing facilities. The contract mandates a total shelf life of 24 months, with a requirement that the detergent possesses at least 21 months of remaining shelf life at the time of delivery. Managed under the Medical Supply Chain Pharm FSA, the performance of this contract is centered in FPO 96660, falling under NAICS code 325412.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Bupivacaine and Epinephrine InjectionThis subcontract involves the supply of Bupivacaine and Epinephrine Injection to prime contractors supporting DLA Troop Support medical supply contracts. The provider must deliver end items compliant with NSN 6505-01-189-3973, utilizing pharmaceutical-grade materials and medical-grade packaging. To qualify, the supplier is required to hold all necessary pharmaceutical manufacturing licenses and maintain FDA approval for the specific drug formulation. Managed by the Department of Defense under the Medical Supply Chain Pharm FSA, the contract specifies the delivery of injectable medication quantities as outlined in the award. The performance location is designated as FPO 09591, and the procurement falls under NAICS code 325412.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Isoniazid Tablet ManufacturingThis subcontract involves the manufacturing of Isoniazid 300 MG tablets for prime contractors supporting Department of Defense pharmaceutical supply contracts through the Medical Supply Chain Pharm FSA. The manufacturer is responsible for producing tablets that conform to United States Pharmacopeia standards, packaged in bottles of 100 units. To execute this contract, the provider must utilize pharmaceutical grade API, specialized tablet pressing equipment, and a USP-compliant quality control laboratory. Strict regulatory adherence is required, including the maintenance of active FDA registration and continuous USP compliance. The performance of this contract is centered in FPO 09591, with the primary objective of delivering finished pharmaceutical products that meet all specified government quality and safety benchmarks.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Tetrahydrozoline Hydrochloride Ophthalmic Solution SupplierThis subcontract involves the supply of Tetrahydrozoline Hydrochloride Ophthalmic Solution, USP (0.05%, 15 ML) to support prime contractors under DLA Troop Support medical supply contracts. The selected provider is responsible for manufacturing or sourcing the pharmaceutical solution in accordance with USP standards, utilizing sterile ophthalmic bottling and packaging. All operations must comply with FDA approval and registration requirements for pharmaceutical manufacturing. The contract is managed by the Department of Defense under the Medical Supply Chain Pharm FSA. Physical deliveries of the ophthalmic solution are to be made to either the prime contractor or the Naval Med Readiness Logistics Command, with the place of performance located in Williamsburg, Virginia.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Tolnaftate Powder, USP 1%This subcontract through the Department of Defense Medical Supply Chain Pharm FSA involves the supply of Tolnaftate Powder, USP 1%, to prime contractors on DLA Troop Support medical supply contracts. The requirement is for 15 bottles of 45 GM powder, identified by NSN 6505014807897, which must strictly adhere to USP 1% standards and the DLA Master List of Technical and Quality Requirements. Eligible providers must possess the necessary pharmaceutical manufacturing and distribution licenses to fulfill the order. The performance of this contract is designated for FPO 09591, with a response deadline set for October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

1 day ago

DEADLINE

in 5 days

AI Contract Overview

The Defense Health Agency Contracting Activity, Western Markets Contracting Division, San Diego, has issued a notice of intent to award a sole source supply contract to Guam Regional Medical City (GRMC) for Neonatal Total Parenteral Nutrition (Neo-TPN) and Methemoglobin Testing. This firm fixed price contract supports the Blood Bank Department at the Naval Hospital Guam, specifically catering to a new 3-bed Neonatal Stabilization Unit that will provide round-the-clock care for critically ill neonates. Highlighted under Federal Acquisition Regulation FAR 13.106-1(b)(1)(i), GRMC is identified as the sole provider on the island capable of meeting the specialized requirements for neonatal TPN and methemoglobin testing, due to the geographical limitations and logistical challenges impacting the availability of alternative suppliers. The Neo-TPN services require specialized nutritional formulas tailored to the unique requirements of premature or critically ill infants, which are compounded specifically for each neonate's physiological and medical needs. Additionally, methemoglobin testing necessitates exclusive equipment and reagents that GRMC uniquely provides within the island's logistical framework. The contract underlines that GRMC is the only facility equipped to deliver these indispensable services efficiently and promptly, ensuring critical medical care for neonates in urgent situations. Potential vendors who wish to challenge the sole source nature of this procurement must submit detailed capability statements by January 30, 2025, as outlined by the notice requirements. All submissions must be digital and formatted in Microsoft Word or Adobe PDF to ensure uniform evaluation by the contracting authority.

General Info

Sole source contract awarded to GRMC for neonatal nutrition and methemoglobin testing services.

Agency

Department Of Defense → DEFENSE HEALTH AGENCY (DHA)

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Place of Performance

Agana Heights, GU, USA

Set-Aside

NONE

Documents

PWS for Neonatal TPN and Methemoglobin Testing - DHA

12 pages · pws

High

PWS - Neo-TPN and Methemoglobin Testing

12 pages · sow

High

HT941025N0022 Notice of Intent to Sole Source

1 page · special-notice

Low

Justification for Non-Competitive Procurement for Neonatal TPN and Methemoglobin Testing at Naval Hospital Guam

3 pages · justification-and-authorization

Low

Justification for Non-Competitive Procurement (JNCP)

3 pages · justification-and-authorization

Low

Notice of Intent to Sole Source HT941025N0022

1 page · notice-of-intent

Low

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

PhaseClosed

PostedJan 15

Combined Synopsis

Response DeadlineJan 30

Deadline has passed

Submission Closed

01/30/2025, 09:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Defense → DEFENSE HEALTH AGENCY (DHA)

Contacts2 people available

OfficeFALLS CHURCH, VA, 22042, USA

Organization / AgencyDepartment Of Defense → DEFENSE HEALTH AGENCY (DHA)

Office AddressFALLS CHURCH, VA, 22042, USA

Contacts

Merlinda Labaco

contact@example.gov

Cassi Jo Newman

contact@example.gov

+1 (555) 000-0000

Full Description

Notice of Intent to Sole Source

HT941025N0022

THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE SUPPLY CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES. The Defense Health Agency Contracting Activity (DHACA), Western Markets Contracting Division (WMCD), San Diego, intends to award a firm fixed price contract for Blank Purchase Agreement (BPA) for Neonatal Total Parenteral Nutrition (Neo-TPN) and Methemoglobin Testing in support of Blood Bank Department, Naval Hospital Guam in accordance with Federal Acquisition Regulation FAR 13.106-1(b)(1)(i), only one source being available to meet the Government’s needs, to:

Guam Regional Medical City (GRMC)

133 Route 3,

Dededo, GU 96929

The neo-TPN and methemoglobin testing services are required to support the establishment of a new 3-bed Neonatal Stabilization Unit, which will provide 24/7 care for critical neonates for up to 10 days at NHG. GRMC is the sole hospital on the island of Guam that can support neonatal TPN and methemoglobin testing for neonatal critical care patients.

Neo-TPN requires highly specialized formulations tailored to the unique nutritional needs of premature or critically ill infants. These formulations often involve specific concentrations designed for critically ill neonates. Neo-TPN solutions must be custom compounded to address the specific needs of each infant based on weight, gestational age, and medical condition. This level of customization and expertise in neonatal care is solely offered at GRMC. The island’s geographical location limits the availability of suppliers who can meet the stringent requirements of neo- TPN. Shipping logistics and distance prevent alternative suppliers from providing the specialized formulations required for critically ill neonatal patients.

Methemoglobin testing requires specific equipment, reagents, and test kits available only at GRMC. The testing must be conducted on the island, and geographical isolation has limited the availability of multiple laboratory test centers. The Naval Hospital Guam (NHG) has identified GRMC as the only reliable testing center within reasonable transportation distance or logistical capability to perform the test. Methemoglobin testing and results are critical in urgent medical situations for critically ill infants, and GRMC is the sole hospital that can quickly provide the necessary services to meet immediate healthcare needs and ensure quality service.

This notice of intent is not a request for competitive proposals, and no solicitation document exists for this requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to provide the required product for United States Naval Hospital Guam. Capability statements shall not exceed six (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source purchase order.

If a vendor challenges the basis of this requirement, please email capability statements as a Microsoft Word or Adobe PDF attachment to Merlinda M. Labaco at Merlinda.m.labaco.civ@health.mil. The closing date for challenges is no later than 1:00 pm Pacific Standard Time, 30 January 2025.

NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED